-
InventisBio Announces Positive Phase II Results for D-2570 in Psoriasis Treatment
•
China-based InventisBio (Shanghai) Co., Ltd (SHA: 688382) announced positive results from the Phase II study for its oral TYK2 inhibitor D-2570 in psoriasis at the American Academy of Dermatology Annual Meeting (AAD). The data demonstrated significant improvements in patients treated with D-2570 compared to the placebo group. Study ResultsAfter 12…
-
InventisBio’s Oral TYK2 Inhibitor D-2570 Achieves Positive Results in Phase II Psoriasis Study
•
China-based InventisBio (Shanghai) Co., Ltd (SHA: 688382) has announced the successful completion of a Phase II study for its oral TYK2 inhibitor, D-2570, in the treatment of psoriasis, with positive outcomes. Understanding Psoriasis and the Role of TYK2 InhibitionPsoriasis is an immune-mediated chronic disease characterized by recurrent, inflammatory, and systemic…
-
InventisBio Acquires Immuno-Oncology Assets from Lyvgen Biopharma in RMB1.5 Million Deal
•
InventisBio (Shanghai) Co., Ltd (SHA: 688382), a Chinese biotechnology company, has announced a transfer agreement with Lyvgen Biopharma, a Shanghai-based specialist in immuno-oncology therapeutics. According to the agreement, Lyvgen will transfer proprietary technology related to no more than three target antibodies to InventisBio, along with licensing patent rights and other…
-
Sino Biopharmaceutical’s KRAS Inhibitor Garsorasib Earns Breakthrough Designation in China
•
Sino Biopharmaceutical Ltd (HKG: 1177), a prominent biopharmaceutical company in China, has announced that its candidate garsorasib (D-1553), a KRAS G12C inhibitor co-developed with InventisBio (Shanghai) Co., Ltd, has been granted Breakthrough Therapy Designation (BTD) by China’s Center for Drug Evaluation (CDE). The designation covers two indications: the treatment of…
-
InventisBio’s KRAS G12C Inhibitor Garsorasib NDA Accepted for Review by China’s NMPA
•
InventisBio (Shanghai) Co., Ltd (SHA: 688382), a China-based pharmaceutical company, has announced that the New Drug Application (NDA) for its candidate garsorasib (D-1553) has been accepted for review by China’s National Medical Products Administration (NMPA). The KRAS G12C inhibitor is intended for the treatment of locally advanced or metastatic non-small…
-
InventisBio’s KRAS G12C Inhibitor D-1553 Advances Toward Priority Review in China
•
According to the China Center for Drug Evaluation (CDE), Shanghai-based InventisBio Co., Ltd. (SHA: 688382) is on track to secure priority review status for its KRAS G12C inhibitor, D-1553, aimed at treating locally advanced or metastatic non-small cell lung cancer (NSCLC) with a confirmed KRAS G12C mutation, particularly in patients…
-
Chia Tai Tianqing Secures Exclusive Rights to InventisBio’s D-1553 in China Licensing Deal
•
China-based Chia Tai Tianqing has signed a licensing agreement with compatriot firm InventisBio, securing exclusive rights to develop, regulate, manufacture, and commercialize InventisBio’s D-1553 in mainland China. The agreement also provides Chia Tai Tianqing with potential ex-China territorial rights based on future data-sharing, although no financial details have been disclosed.…
-
Betta Pharmaceuticals’ MCLA-129 Combo Therapy for NSCLC Gets NMPA Clinical Approval
•
China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its bispecific antibody, MCLA-129, in combination with befotertinib for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). The treatment…
-
Betta Pharmaceuticals’ Befotertinib Approved by China’s NMPA for EGFR-Mutated NSCLC
•
China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced receiving market approval from the National Medical Products Administration (NMPA) for its third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), befotertinib, for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with the EGFR T790M mutation that has…
-
Mirati Therapeutics Sues InventisBio Over Trade Secret Misappropriation
•
US-based Mirati Therapeutics (Nasdaq: MRTX) is reportedly suing China-based InventisBio Co., Ltd (SHA: 688382) over allegations of trade secret misappropriation. According to a security exchange notice from InventisBio, Mirati has filed a lawsuit in the Shanghai Intellectual Property Court, requesting an injunction, damages, and confirmation of ownership of certain patents.…
-
InventisBio Raises USD 308M in Shanghai STAR IPO, Valued at USD 1.54B
•
China-based biotech firm InventisBio (SHA: 688382) has completed an initial public offering (IPO) of 115 million shares on the Shanghai Stock Exchange’s Science and Technology Innovation Board (STAR). The shares were priced at RMB 18.12 (USD 2.68) each, raising a total of RMB 2.08 billion (USD 308 million) and valuing…
-
InventisBio’s KRAS G12C Inhibitor D-1553 Earns CDE Breakthrough Therapy Status
•
China-based InventisBio (Shanghai) Co., Ltd announced receiving breakthrough therapy designation (BTD) status for its KRAS G12C inhibitor D-1553 from the Center for Drug Evaluation (CDE), marking the first such recognition in China. Drug Profile and Clinical TrialsD-1553 is a highly efficient and selective KRAS G12C inhibitor undergoing a global multi-center…
